18.04.2017 • NewsDede WillamsoxygenTumor

FDA Approves NuvOx IND Brain Tumor Trial

(c) Steve Debenport/Getty Images
(c) Steve Debenport/Getty Images

The US Food and Drug Administration (FDA) has approved NuvOx Pharma’s application to proceed with Phase 2 clinical trials for an Investigational New Drug (IND) to initiate a Phase II clinical trial for its oxygen therapeutic, NVX-108, in patients with the hypoxic solid brain tumor glioblastoma multiforme (GBM).

The injectable drug is designed to reduce tumor hypoxia in order to make tumors more sensitive to radiation therapy and chemotherapy. It works by traveling through the bloodstream, first picking up oxygen in the lungs before proceeding to hypoxic tissue where it passively delivers the oxygen.

Hypoxic tumors are resistant to radiation therapy and certain kinds of chemotherapy. The trial’s principal investigator, Baldassarre Stea, said tumor hypoxia is known to be a problem in many tumor types, including GBM. By increasing tumor oxygen levels, he said the NuvOx drug is designed to improve the effectiveness of these therapies to kill cancer cells more effectively and increase patient survival. “Clinical trials are needed to see if NVX-108 can become approved by regulators,” Stea noted.

The US clinical stage biopharmaceutical company based in Tucson, Arizona, is developing a platform of oxygen therapeutics to treat life-threatening diseases where hypoxia plays a role. It said pre-clinical data has shown efficacy in several indications including hypoxic solid tumors, stroke, sickle cell crisis, hemorrhagic shock, traumatic brain injury and myocardial infarction. Compared to prior fluorocarbons, NuvOx’s DDFPe is claimed to be active at less than 1/200th the dose.

In addition to the just approved oncology trial, the Arizona biotech firm also has a product in a Phase Ib/II clinical trial to treat acute ischemic stroke and an IND approval for a Phase Ib clinical trial for sickle cell crisis.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
19.05.2025 • NewsChemie

OQ Chemicals firmiert künftig wieder als Oxea

Der bis Mai 2020 unter dem Namen Oxea bekannte Hersteller von Oxo-Zwischenprodukten und Oxo-Derivaten, der zwischenzeitlich zum Omanischen Energieunternehmen OQ gehörte und unter dem Namen OQ Chemicals firmierte, kehrt zu seinem alten Namen und seinen Wurzeln zurück.